How to Vet a Healthcare Marketing Expert for Admissions

The AMA’s Opinion 9.6.1 is not a marketing constraint to work around. It is the operating standard a healthcare marketing expert should be able to recite from memory. The policy frames physician advertising restrictions narrowly: they exist to prevent deception, not to suppress promotion ². That distinction matters for a CMO building a vendor scorecard, because it shifts the question from “what can we say?” to “what can we substantiate, present in context, and defend if challenged?”

The Code of Medical Ethics organizes its guidance on physician communications across opinions covering confidentiality, advertising, and media relations, treating public-facing speech as an extension of the clinical relationship rather than a separate commercial activity ¹. A partner who treats admissions creative as ordinary direct-response work — testimonials stripped of context, before-and-after framing, vague recovery promises — is working from a different rulebook than the one clinical leadership operates inside.

The vetting move is straightforward. Ask the partner to walk through a recent campaign and identify three things: the material information disclosed to prospective patients, the specific claims that could create unjustified expectations, and the documentation trail for both. A competent partner produces this without hesitation. A generic healthcare marketer treats the question as a compliance interruption and redirects to performance metrics.

Most admissions campaigns fail their first serious legal review at the same point: an outcome claim, a success rate, or an implied benefit that no one on the marketing side can defend with a paper trail. The FTC’s Health Products Compliance Guidance, updated in December 2022, is explicit about what defense looks like. Marketers must “consider what express and implied messages consumers are likely to take” from a piece of creative and “carefully review the support for each claim” to confirm it is scientifically sound ³.

That standard collapses into a working artifact: a substantiation file. A competent partner should be able to produce one on demand for any health-related claim running in market. The file documents:

• the express message,
• the implied messages a reasonable consumer would take,
• the scientific support relied on,
• the study design and population,
• the limitations of that evidence, and
• the date of the most recent review ³.

A vendor who has never assembled one — or who treats the request as excessive — is not a behavioral health partner. They are a lead-gen vendor working in a regulated space without the right paperwork.

Implied messages are where most agencies stumble. A landing page headline reading “Get your life back” is not a literal outcome claim, but the FTC’s analysis turns on what consumers reasonably take from the message, not what the marketer intended ³. A photograph of a smiling family next to language about “proven recovery” carries a substantiation burden even when no percentage appears on the page. Vetting should include a walkthrough of how the partner audits implied claims in active creative, not just the headline assertions a junior reviewer would flag.

Regulatory fluency is not a static credential. A partner who passed a 2020 compliance check may be working from a rulebook that no longer applies. The cleanest currency test available to a CMO right now is SAMHSA’s 42 CFR Part 8 final rule, updated in February 2024 and effective October 2024, which restructured admission criteria and operational flexibility for opioid treatment programs ¹⁷.

The substantive changes matter for admissions messaging. Admission requirements no longer rely on the prior one-year opioid addiction threshold or documentation of multiple failed detox attempts, and the rule expands evidence-based delivery models including telehealth pathways ¹⁷. The proposal phase, summarized by the American Hospital Association in late 2022, signaled the direction of travel a year before the rule landed ¹². A partner tracking the sector should have adjusted OTP client landing pages, paid search copy, and intake scripts to reflect the new eligibility language well before the effective date.

Ask the partner directly: how did the 2024 OTP rule change the campaigns they run for opioid treatment clients? A current partner answers with specifics — copy updates, eligibility FAQ revisions, telehealth-pathway landing pages. A partner who needs to look it up, or who conflates 42 CFR Part 8 with Part 2 confidentiality rules, is not operating with the regulatory currency a treatment center license depends on.

Stigma toward people with substance use disorders persists across health professionals, driven by moral models of SUD and gaps in addiction-specific training, and stigmatizing language in public communications discourages treatment seeking in the exact population an admissions campaign is trying to reach ⁴. The implication for vendor vetting is direct: creative that uses outdated terminology is not a stylistic preference. It is a measurable drag on conversion among prospects already weighing whether to make the call.

NIDA’s Words Matter guidance translates the research into a working terminology standard:

• “Person with a substance use disorder” replaces “addict” or “abuser.”
• “Positive” or “negative test result” replaces “clean” or “dirty.”
• “Person in recovery” replaces “former addict.”
• “Medication for opioid use disorder” replaces “substitution” or “replacement therapy.”

NIDA frames the standard plainly: feeling stigmatized reduces willingness to seek treatment, and communicators should take all steps necessary to reduce the potential for stigma and negative bias ⁵.

A competent partner conducts a language audit as a standing creative-review step, not a one-time cleanup. The audit covers:

• paid search headlines and descriptions,
• landing page H1s and body copy,
• image alt text,
• retargeting ad variants,
• call-script openings,
• voicemail templates, and
• the form-confirmation and email-nurture sequences that follow a submission.

It also extends to family-facing pages, where “loved one struggling with addiction” requires the same scrutiny as patient-facing copy.

The vetting move: ask the partner to produce a redlined sample of their own prior creative against the NIDA standard. A partner who has done the work hands over a marked-up artifact. A partner who has not done the work argues that their copywriters “already know” — which is the response the underlying stigma research predicts and warns against ⁴.

Most vendor pitches end at the form fill. The admissions pipeline does not. The conversion that matters — the qualified call that becomes a VOB conversation and then an admission — runs through a spoken exchange where the prospect or family member is often distressed, time-pressured, and parsing insurance language they have never encountered. A marketing partner who cannot speak to call-stage communication craft is handing the CMO a lead and walking away from the place where the lead is actually won or lost.

AHRQ’s spoken-communication toolkit gives the standard. The agency recommends a universal-precautions approach to health literacy, treating every patient interaction as if comprehension may be limited, and using teach-back — asking the caller to repeat back what they heard in their own words — to confirm understanding before moving forward ⁶. Applied to admissions intake, that means the VOB conversation does not end when the benefits are read aloud. It ends when the caller can restate, in plain language, what their plan covers, what the next step is, and when they will hear back.

A competent partner shows up to the vetting conversation with artifacts:

• an intake script with teach-back checkpoints at benefits explanation, level-of-care recommendation, and next-step confirmation;
• a plain-language glossary substituting “the portion you pay” for “coinsurance”; and
• a QA rubric scoring calls on comprehension confirmation, not just call duration or disposition.

Centralized review of these artifacts across marketing, clinical intake, and compliance reflects the coordination AHRQ recommends for any health-services outreach program ¹⁵.

One bright line should never be crossed. SAMHSA’s National Helpline is a free, confidential, 24/7, 365-day-a-year treatment referral and information service available in English and Spanish ¹⁶. It is public infrastructure. Paid search creative, landing pages, and chat widgets that mimic the helpline’s framing, suggest a public-resource affiliation that does not exist, or position a private intake line as the federal referral service misrepresent the public safety role of that infrastructure.

The vetting test is concrete. Review the partner’s active paid search ad copy for any branded or implied use of “national,” “helpline,” “hotline,” or government-style language without clear sponsor identification. Review crisis-keyword bidding strategy: does the partner bid on suicide and overdose terms, and if so, what is the routing protocol when the caller’s need exceeds the center’s level of care? A partner without a documented answer is not ready for crisis-adjacent traffic.

The reporting layer is where most agency relationships go quietly wrong. Impressions climb, click-through rates look healthy, the monthly deck is full of green arrows, and admissions volume sits flat. A partner with evidence discipline does not lead with traffic. They lead with the chain that connects spend to a qualified call, a completed VOB, and an admission — and they are explicit about where the chain breaks.

The peer-reviewed review of digital marketing in healthcare names the trade-off directly: post-pandemic acceleration has expanded reach, but campaigns must balance growth ambitions with ethical communication, data protection, and accurate health information ⁷. Volume that comes from misinformation-adjacent creative or aggressive crisis-keyword bidding is not progress. It is liability with better attribution.

The tech-rhetoric problem is adjacent and worth naming. Vendors increasingly pitch AI personalization, predictive lead scoring, and conversational agents as admissions accelerants. The consumer-engagement-in-health-IT analysis pushes back: optimistic narratives about engagement technology routinely outrun the empirical evidence, and serious work requires better data on whether these tools actually move national health goals ⁸. A competent partner can describe what their AI stack does, what it has been measured against, and where it has failed. A partner who answers “AI” to every question about attribution, personalization, or conversion is selling rhetoric.

Experience claims are the second-most-common audit failure after outcome claims. “Compassionate care,” “family-centered approach,” “industry-leading patient experience” — these appear on nearly every treatment center website, and almost none of them are tied to a measurement instrument the FTC would recognize as substantiation.

AHRQ’s CAHPS Outpatient Mental Health Survey collects standardized data on adult experiences with mental health and substance use disorder services across settings, covering access, communication, and coordination ¹¹. The broader CAHPS literature documents how patient-experience survey data supports patient-centered improvement and quality initiatives when administered systematically, as NCQA recommends for medical-home transformation ¹⁰. A partner who treats experience as a creative talking point rather than a measured construct cannot defend an experience claim under scrutiny.

The vetting move is to ask the partner how they would substantiate the experience language on a client’s existing landing page. A competent answer references CAHPS-aligned items the center either already collects or could collect, names the specific composites (access, communication, coordination) the claim maps to, and proposes a review cadence. A weak answer offers more testimonials. Testimonials are not substantiation under the FTC framework; standardized survey data is.

Case studies are the artifact every agency offers and almost no one inspects properly. The standard reading — admissions up, cost per lead down, a quote from the COO — answers none of the questions a CMO building a defensible scorecard actually needs answered. Inspection should run through the three domains the rest of this article has built out.

On regulatory and ethical fluency, the case study should reference the substantiation file behind any outcome or experience figure cited, and the creative samples shown should be defensible under the AMA standard that promotional communications be truthful, non-misleading, and free of unjustified expectations ². If a success rate appears in the deck with no methodology footnote, the partner has just demonstrated the failure mode.

On behavioral-health communication craft, the case study should include before-and-after creative showing a language audit applied, and intake-script excerpts or QA rubrics demonstrating teach-back checkpoints at the call stage. On evidence discipline, the case study should show the attribution model used, the patient-experience signals tracked alongside conversion, and at least one honest account of what did not work and why.

A case study without these elements is a marketing artifact about marketing. A case study with them is a working document a CMO can defend to clinical leadership, compliance, and the CFO in the same meeting.